Blog
-
Industry News
Zepbound vs. Mounjaro: A Comparison for Weight Management and Diabetes Control
Key Takeaways Same ingredient, different approvals – Both Zepbound and Mounjaro contain tirzepatide, but Zepbound is FDA-approved for chronic weight management, while Mounjaro is approved for type 2 diabetes. Weight loss outcomes – Clinical trials show Zepbound users achieve greater average weight loss (up to ~22%) compared with Mounjaro users (~15%), reflecting its weight-focused dosing…
-
Industry News
Novo Nordisk Lowers U.S. Cost of Ozempic® (semaglutide) for Self-Paying Patients
August 2025: Ozempic® Price Reduction for Type 2 Diabetes Patients What You Need to Know About Ozempic® Pricing Changes On August 18, 2025, Novo Nordisk announced a significant reduction in the out-of-pocket cost of Ozempic® (semaglutide) for U.S. patients with type 2 diabetes. The new price is $499 per month, down from the previous cost…